Infection with the frequently transmitted hiv-1 m41l variant has no influence on selection of tenofovir resistance

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 573-580

  Pingen, Marieke ^a,b   Nijhuis, Monique ^a   Mudrikova, Tania ^a   Van laarhoven, Arjan ^a   Langebeek, Nienke ^c   Richter, Clemens ^c   Boucher, Charles A B ^b   Wensing, Annemarie M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Atripla ; Drug resistance; Emtricitabine; Transmission; Truvada

Indexed keywords

EMTRICITABINE; TENOFOVIR; ADENINE; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BACTERIAL MUTATION; BACTERIAL TRANSMISSION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SENSITIVITY; EC50; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO SELECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYLOGENY; VIRUS REPLICATION; AMINO ACID SUBSTITUTION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLASSIFICATION; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MOLECULAR EVOLUTION; MUTATION; PHENOTYPE; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; AMINO ACID SUBSTITUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; PHENOTYPE; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84922475634     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku377     Document Type: Article

References (34)

1. Wheeler WH, Ziebell RA, Zabina H et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24: 1203-12.
2. Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
3. SPREAD Programme. Recent dynamics of transmitted drug resistance in Europe: SPREAD programme 2006-2007. Abstract O_13. Rev Antivir Ther Infect Dis 2011; 2: 15-6.
4. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 1393-401.
5. Pingen M, Nijhuis M, de Bruijn JA et al. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011; 66: 1467-80.
6. Brenner BG, Roger M, Routy JP et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195: 951-9.
7. Yerly S, Junier T, Gayet-Ageron A et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009; 23: 1415-23.
8. Hofstra LM, Nijhuis M, Pingen M et al. Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatmentnaive patients. J Antimicrob Chemother 2013; 68: 1246-50.
9. Brenner B, Wainberg MA, Roger M. Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS 2013; 27: 1045-57.
10. Boucher CA, O'Sullivan E, Mulder JWet al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105-10.
11. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.
12. Margot NA, Isaacson E, McGowan I et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227-35.
13. Ross LL, Parkin N, Gerondelis P et al. Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility. J Acquir Immune Defic Syndr 2006; 43: 567-70.
14. Barrios A, de Mendoza C, Martin-Carbonero L et al. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. J Clin Microbiol 2003; 41: 4421-3.
15. Brenner BG, OliveiraM, Doualla-Bell F et al. HIV-1 subtype Cviruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20: F9-13.
16. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
17. Margot NA, Lu B, Cheng A et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006; 7: 442-50.
18. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006; 50: 4087-95.
19. Sluis-Cremer N, Sheen CW, Zelina S et al. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2007; 51: 48-53.
20. Rhee SY, Taylor J, Wadhera G et al. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 2006; 103: 17355-60.
21. van Maarseveen NM, Huigen MC, de Jong D et al. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods 2006; 133: 185-94.
22. Boucher CA, KeulenW, van Bommel T et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996; 40: 2404-9.
23. Johnson VA, Calvez V, Gunthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-64.
24. Pineda-Pena AC, Faria NR, Imbrechts S et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 2013; 19: 337-48.
25. Huigen M, Albert J, Lindström A et al. Compensatory fixation explains long term persistence of the M41L in HIV-1 reverse transcriptase in a large transmission cluster. Antivir Ther 2006; 11 Suppl 1: S113 (Abstract 100).
26. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194 Suppl 1: S51-8.
27. Segondy M, Montes B. Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1. J Acquir Immune Defic Syndr 2005; 38: 110-1.
28. Valer L, Martin-Carbonero L, de Mendoza C et al. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 2004; 18: 2094-6.
29. Parikh UM, Bacheler L, Koontz D et al. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 4971-7.
30. Parikh UM, Barnas DC, Faruki H et al. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006; 194: 651-60.
31. Parikh UM, Zelina S, Sluis-Cremer N et al. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007; 21: 1405-14.
32. von Wyl V, Ehteshami M, Symons J et al. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis 2010; 201: 1054-62.
33. Lengruber RB, Delviks-Frankenberry KA, Nikolenko GN et al. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J Antimicrob Chemother 2011; 66: 702-8.
34. Karlsson A, Bjorkman P, Bratt G et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012; 7: e33484.